Advances in Fertility Preservation for Pediatric and Adolescent Cancer Patients

Infertility is a common consequence of treatment for pediatric malignancies, often caused by exposure to alkylating agents as well as radiation therapy. As cure rates for pediatric cancer have continued to improve, more children are surviving well into their reproductive years. Our Cancer Survivorship Program has developed a novel Fertility Preservation Program to improve our approach to fertility preservation at diagnosis. We are diligent in identifying and counseling all males and females at risk for infertility. We are also able to offer options for both pre-pubertal and pubertal males and females facing gonadotoxic therapies. This lecture will review cancer therapies that pose a risk to our patients’ fertility and we will describe our novel fertility preservation program that offers standard options as well as emerging investigation options in our young patients.

Learning Objectives:

  1. Identify cancer therapies associated with an increase risk for future infertility in pediatric and adolescent patients
  2. Review current standard clinical care options for fertility preservation in males and females
  3. Discuss emerging investigational options for fertility preservation in males and females

Speaker:

This seminar focuses on oncology and was delivered at a virtual event titled, “Advances in Fertility Preservation for Pediatric and Adolescent Cancer Patients,” on March 23, 2022.

Additional CHOP Resources:

Content Disclaimer

The Terms of Use and Privacy Policy set forth on the website of The Children’s Hospital of Philadelphia apply to any and all uses of and access to this site and the content found here.

The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.

CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.

To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.

Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.

You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.

The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.

 

By starting this module, you agree to our Content Disclaimer and Terms of Service.

Not Enrolled

Course Includes

  • 2 Lessons
  • Course Certificate